Pharma customers set to benefit from proprietary metal coordination chemistry as Recipharm enters its first dual promotion agreementmore

Recipharm’s solid dose facility located in Fontaine, France, has been approved for supply of manufactured products to Japan’s pharmaceuticals market following a recent inspection by the PMDA, the Japanese drug agency.more

Recipharm and PledPharma announce FDA approval of an IND application for Phase IIb clinical trial with PledOx, PLIANT, in the U.S. The material for PLIANT has been manufactured by Recipharm Pharmaceutical Development.more

Recipharm Pharmaceutical Development AB is pleased to announce the appointment of Dr. Hans Lennernäs to the company's Board of Directors.more

Director of Catalan Institute for Water Research awarded accolade in recognition of environmental research to minimise impact of pharmaceutical residuesmore

In order to strengthen its contract development business Recipharm has appointed Ann Flodin to a new position as European Sales Manager with a primary focus on South of Sweden and Denmark.more

Facility in Solna, Sweden, is set for significant capacity expansion. 4th December 2012: Recipharm has today announced a significant strategic investment to expand capacity in analytical services and stability studies at its facility in Solna, Sweden.more

Recipharm and Vetcare have today announced the signing of an agreement for the development and manufacture of a parenteral veterinary product. Specifically, the product concerned will be developed by Recipharm’s development site in Solna, Sweden and the commercial manufacturing is intended to take place at the company’s site in Monts, France.more

Accolade recognises the emergence of Recipharm as one of the world’s leading CDMOs with a 2.2 Billion SEK annual turnover.more

Recipharm AB and Astimex Pharma AB have today announced the formation of a collaboration agreement for the development and manufacture of a pharmaceutical product. The formulation development work will take place at the Recipharm Pharmaceutical Development site located in Solna close to Stockholm. Astimex Pharma also has the opportunity to choose Recipharm as the future manufacturer for the product.  more